At a current market capitalisation of approximately A$150 million , Paradigm Biopharmaceuticals appears materially undervalued when compared to peers advancing osteoarthritis (OA) disease modifying therapies, particularly Kolon TissueGene , whose valuation translates to ~A$55 per share at today’s exchange rates. Kolon’s lead asset, TG‑C , is a gene modified, allogeneic cell therapy combining irradiated chondrocytes with HEK293 cells overexpressing TGF‑β1, and is currently in a global Phase 3 trial for knee OA.Read more
Paradigm Biopharmaceuticals (ASX: PAR) on Cusp of Transformation with Potential FDA Approval of Osteoarthritis Drug Zilosul® Melbourne, Australia - Paradigm Biopharmaceuticals (ASX: PAR), a late-stage drug development company, is poised at a critical juncture as it progresses its lead drug candidate, Zilosul® (injectable pentosan polysulfate sodium), through Phase 3 clinical trials for the treatment of osteoarthritis (OA). A successful outcome and subsequent clearance from the U.S. Food and Drug Administration (FDA) could unlock a multi-billion dollar market and fundamentally reshape the company's future, offering a new treatment paradigm for millions suffering from the debilitating joint disease.Read more
Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. Its lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is headquartered in Melbourne, Australia.
